XXXX antagonists for @entity5135 , @entity1459 and @entity741 : therapeutic tool and probe for identification of pathophysiologic mechanisms.

@entity1 @entity2749 @entity63 @entity1423 @entity1855 @entity26 @entity731 @entity3361 @entity3362 @entity301 @entity3988 @entity1459 @entity951 @entity460 @entity594 @entity741 @entity5135 @entity715
The @entity460 antagonists provide a unique tool to reduce myocardial @entity26 demand and prevent increases in coronary vasomotor tone. For @entity1 with @entity5135 , @entity3988 , @entity594 and @entity1855 are extremely effective in preventing @entity2749 of @entity3361 and symptoms of @entity63 . Unstable @entity951 is a more complex pathophysiologic syndrome with @entity2749 of @entity63 due to increases in coronary vasomotor tone, intermittent @entity1423 or alterations in the underlying @entity731 . Each of the @entity460 antagonists is effective as monotherapy in decreasing the frequency of @entity951 at rest. @entity594 is the only @entity460 antagonist that has been studied in a combination regimen with beta blockers and @entity3362 for @entity1 with @entity1459 , and control of @entity951 is better with the combination regimen than with either form of therapy alone. Although symptoms of @entity741 in @entity1459 are reduced by @entity460 antagonists, these agents do not seem to decrease the incidence of adverse outcomes. Antiplatelet therapy appears to improve morbidity and mortality in @entity1 with @entity1459 , suggesting that @entity715 formation may play a central role in that disorder. Episodes of silent or asymptomatic @entity741 , identified by ST-segment monitoring, occur in a variety of disorders of @entity301 . Among @entity1 with @entity5135 and @entity1459 , @entity2749 of silent @entity63 appear to be as frequent as @entity2749 of @entity951 and the @entity460 antagonists are effective in decreasing @entity2749 of @entity63 regardless of the presence or absence of symptoms. Persisting @entity2749 of silent @entity63 among @entity1 with @entity1459 despite maximal medical therapy identify @entity1 at high risk for an early unfavorable outcome. Among @entity1 with stable exertional @entity951 , @entity2749 of silent @entity63 may be up to 5 times as frequent as @entity2749 of @entity951 , and may be due to increases in coronary vasomotor tone, transient @entity1423 or increases in myocardial @entity26 demand. Preliminary experience suggests that @entity460 antagonists and beta blockers are effective in decreasing @entity2749 of silent @entity63 in @entity1 with stable exertional @entity951 and that a combination regimen may be more effective than either form of therapy alone.
